Seeking Alpha

allstar0088

allstar0088
Send Message
View as an RSS Feed
View allstar0088's Comments BY TICKER:
Latest  |  Highest rated
  • MannKind's Afrezza: Another Look At The Early Adopters [View article]
    Your links are not as relevant as you think they are.
    Jul 1, 2015. 07:56 PM | 2 Likes Like |Link to Comment
  • My Updated Thoughts On MannKind [View article]
    Your links are not as relevant as you think they are.
    Jun 16, 2015. 06:11 AM | 1 Like Like |Link to Comment
  • My Updated Thoughts On MannKind [View article]
    Remember...confirmation bias...its a b*tch.
    Jun 14, 2015. 03:01 PM | Likes Like |Link to Comment
  • My Updated Thoughts On MannKind [View article]
    Sanofi has stated very clearly what it intends to do with Afrezza:

    http://bit.ly/1Iy5VF5
    Jun 14, 2015. 10:53 AM | 1 Like Like |Link to Comment
  • More Products On The Way For MannKind? [View article]
    This link is more representative of what the French are thinking:

    http://bit.ly/1Iy5VF5
    Jun 14, 2015. 10:50 AM | 1 Like Like |Link to Comment
  • Sorrento Therapeutics And L.A.'s Richest Man Ally, Target Celgene's Blockbuster Abraxane [View article]
    Even MNKD was up 18% today. Most likely a beneficiary of good buzz from the Jefferies conference and the ADA meeting this past weekend. Lets see if it continues this week with the Goldman conference.
    Jun 8, 2015. 09:19 PM | Likes Like |Link to Comment
  • More Products On The Way For MannKind? [View article]
    Does anyone recognize this guy?

    http://bit.ly/1Iy5VF5
    Jun 8, 2015. 10:17 AM | 8 Likes Like |Link to Comment
  • MannKind's (MNKD) Management Presents at Jefferies Global Healthcare Conference (Transcript) [View article]
    Amy Tenderich had plenty to say on Twitter about Afrezza at ADA:

    http://bit.ly/1HhMVcb

    Matt Pfeffer on Twitter? First post on Feb 14.

    http://bit.ly/1KjAbmh
    Jun 8, 2015. 06:11 AM | Likes Like |Link to Comment
  • MannKind's Afrezza Inhaled Insulin: A Game Changer For Seniors With Diabetes [View article]
    Wow. Big pharma charging premium prices for a new drug. That's never been done thousands of times before.
    Jun 2, 2015. 09:44 PM | Likes Like |Link to Comment
  • Mannkind: Flawed? No Competition? Overall Superior Drug? [View article]
    For a more sober view on medical costs for diabetics:

    http://bit.ly/1SU1nvA

    http://bit.ly/1dcLNdC
    Jun 2, 2015. 03:46 PM | Likes Like |Link to Comment
  • MannKind's Afrezza Inhaled Insulin: A Game Changer For Seniors With Diabetes [View article]
    Lets remind everyone that Mannkind has already received $200 million from Sanofi since last year. Investors take note.
    May 25, 2015. 02:55 PM | 3 Likes Like |Link to Comment
  • MannKind's Afrezza Inhaled Insulin: A Game Changer For Seniors With Diabetes [View article]
    Some early adopters have reported "life-changing" results precisely because they don't have to carb count with Afrezza and some have also reported that they need less basal insulin, probably because they have become more insulin-sensitive since beginning Afrezza use. Of course, this is all anecdotal. But it's interesting to compare what should happen according to traditional modes of thinking about diabtes, and what is actually occurring in PWD using Afrezza.
    May 25, 2015. 12:12 PM | 1 Like Like |Link to Comment
  • Afrezza's Slow Launch: It's Still Early, But I Kinda Told You So [View article]
    Yes, Sanofi has given $200 million to Mannkind since last year precisely because it doesn't believe this Afrezza stuff works. I will take such a lukewarm embrace any day.
    May 12, 2015. 01:37 PM | 8 Likes Like |Link to Comment
  • Analyst downgrades MannKind on lackluster prospects for Afrezza [View news story]
    @Investing Doc

    As stated in the FDA's own documents, "before initiating Afrezza perform...spirometry (FEV1) to identify potential lung disease in all patients." Of course, asthmatics and individuals with chronic lung disease, for whom the drug is contraindicated, will not perform well on such tests. Clinical studies have shown a small decline in FEV1 values (up to 2 years of observation). The FDA docs also say "assess pulmonary function (e.g. spirometry) at baseline." If you have a problem with the use of the term "baseline" then take it up with the FDA.

    As further shown in the FDA docs, "A decline in FEV1 of ≥ 15% occurred in 6% of AFREZZA-treated subjects compared to 3% of comparator-treated subjects." The FDA advises discontinuation of use if decline is greater than or equal to 20% in FEV1 from baseline (there goes that word again).
    May 12, 2015. 06:58 AM | 1 Like Like |Link to Comment
  • Analyst downgrades MannKind on lackluster prospects for Afrezza [View news story]
    @johnchowmd

    You're so right. The test for FEV1 is just a baseline measure. After first 6 months of treatment its measured again and compared against the initial test; and then the test is done yearly thereafter. If you don't already know you're asthmatic or have COPD, you'll surely find out after the test.

    This claim about a detailed medical history being an impediment is bogus. Whenever you go see a new doctor he makes you fill out a new patient questionnaire that, for the most part, is several pages long. It's not the doctor who's filling it out, its the patient. Of course, if you ask the same doctor you've been seeing for years if you could try Afrezza, he would already have your medical history on file.

    All these FUDsters are trying to make getting a prescription for Afrezza seem like a day at the DMV. According to early adopters' feedback, the only worries they've had is whether or not insurance will cover it.
    May 11, 2015. 06:06 PM | 5 Likes Like |Link to Comment
COMMENTS STATS
411 Comments
1,278 Likes